Fig. 2From: Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohortKaplan-Meier plot of retention times for eligible TNFi, OMA, and JAKi treatment courses. JAKi, Janus kinase-inhibitor; OMA, other modes of action; TC, treatment course; TNFi, Tumour necrosis factor-inhibitorBack to article page